{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:28:51Z","timestamp":1792056531964,"version":"4.4.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.intimp.2024.111606","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T08:43:49Z","timestamp":1707900229000},"page":"111606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review"],"prefix":"10.1016","volume":"129","author":[{"given":"Donald C.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Elmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin R.","family":"Arnall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Strassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.111606_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2024.111606_b0010","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111606_b0015","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.intimp.2024.111606_b0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic Complications of Immune Checkpoint Inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist."},{"issue":"5","key":"10.1016\/j.intimp.2024.111606_b0025","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1111\/hae.14632","article-title":"Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system","volume":"28","author":"Moore","year":"2022","journal-title":"Haemophilia."},{"key":"10.1016\/j.intimp.2024.111606_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109015","article-title":"Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system","volume":"110","author":"Moore","year":"2022","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111606_b0035","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0598-9","article-title":"Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports","volume":"7","author":"Noseda","year":"2019","journal-title":"J. Immunotherapy Cancer"},{"key":"10.1016\/j.intimp.2024.111606_b0040","unstructured":"United States Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers."},{"issue":"7","key":"10.1016\/j.intimp.2024.111606_b0045","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci."},{"key":"10.1016\/j.intimp.2024.111606_b0050","article-title":"Drug-induced thrombocytopenia: pathogenesis, evaluation, and management","volume":"152\u20138","author":"George","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"7","key":"10.1016\/j.intimp.2024.111606_b0055","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.3390\/jcm9072212","article-title":"Pathophysiology and diagnosis of drug-induced immune thrombocytopenia","volume":"9","author":"Vayne","year":"2020","journal-title":"J Clin Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.111606_b0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"issue":"3","key":"10.1016\/j.intimp.2024.111606_b0065","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/annonc\/mdv580","article-title":"Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells","volume":"27","author":"Kanameishi","year":"2016","journal-title":"Ann Oncol."},{"key":"10.1016\/j.intimp.2024.111606_b0070","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2015.10.073","article-title":"Two cases of immune thrombocytopenia associated with pembrolizumab","volume":"54","author":"Le Roy","year":"2016","journal-title":"Eur J Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2024.111606_b0075","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunother Cancer."},{"issue":"7","key":"10.1016\/j.intimp.2024.111606_b0080","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdx159","article-title":"Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin's lymphoma","volume":"28","author":"Bulbul","year":"2017","journal-title":"Ann Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2024.111606_b0085","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000477968","article-title":"Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient","volume":"40","author":"Karakas","year":"2017","journal-title":"Oncol Res Treat."},{"issue":"2","key":"10.1016\/j.intimp.2024.111606_b0090","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/annonc\/mdx693","article-title":"A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor","volume":"29","author":"Leroy","year":"2018","journal-title":"Ann Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2024.111606_b0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/imt-2017-0100","article-title":"Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab","volume":"10","author":"Jotatsu","year":"2018","journal-title":"Immunotherapy."},{"issue":"6","key":"10.1016\/j.intimp.2024.111606_b0100","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000479237","article-title":"A Case of Immune Thrombocytopenia as a Rare Side Effect of an Immunotherapy with PD1-Blocking Agents for Metastatic Melanoma","volume":"44","author":"Pfohler","year":"2017","journal-title":"Transfus Med Hemother."},{"issue":"9","key":"10.1016\/j.intimp.2024.111606_b0105","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/CAD.0000000000000664","article-title":"Pseudoprogression with subsequent complete response and severe thrombocytopenia to checkpoint inhibitor immunotherapy in a patient with advanced mucosal melanoma of the sinonasal cavity","volume":"29","author":"Philipp","year":"2018","journal-title":"Anticancer Drugs."},{"issue":"1","key":"10.1016\/j.intimp.2024.111606_b0110","first-page":"73","article-title":"Lethal thrombocytopenia in a patient treated with avelumab for metastatic Merkel cell carcinoma","volume":"17","author":"Kratzsch","year":"2019","journal-title":"J Dtsch Dermatol Ges."},{"key":"10.1016\/j.intimp.2024.111606_b0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2019.02.006","article-title":"A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia","volume":"112","author":"Berger","year":"2019","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.intimp.2024.111606_b0120","first-page":"100871","article-title":"Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer","volume":"28","author":"Mori","year":"2019","journal-title":"Respir Med Case Rep."},{"key":"10.1016\/j.intimp.2024.111606_b0125","doi-asserted-by":"crossref","unstructured":"Li J, Deng X, Wang B, Li W. Fatal outcome of atezolizumab in a patient with immune-mediated pneumonitis, thrombocytopenia, and cardiac dysfunction: A case report Int J Clin Pharmacol Ther. Dec 2019;57(12):607-611. doi:10.5414\/CP203448.","DOI":"10.5414\/CP203448"},{"key":"10.1016\/j.intimp.2024.111606_b0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejca.2019.08.003","article-title":"Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab","volume":"121","author":"Song","year":"2019","journal-title":"Eur J Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2024.111606_b0135","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s13256-019-2245-y","article-title":"Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature","volume":"13","author":"Hasegawa","year":"2019","journal-title":"J Med Case Reports"},{"issue":"2","key":"10.1016\/j.intimp.2024.111606_b0140","doi-asserted-by":"crossref","first-page":"877","DOI":"10.21873\/invivo.11852","article-title":"Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review","volume":"34","author":"Mouri","year":"2020","journal-title":"In Vivo. Mar-Apr"},{"key":"10.1016\/j.intimp.2024.111606_b0145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejca.2020.02.043","article-title":"A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab","volume":"131","author":"Matsumoto","year":"2020","journal-title":"Eur J Cancer."},{"issue":"7","key":"10.1016\/j.intimp.2024.111606_b0150","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1177\/1078155220913081","article-title":"Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia","volume":"26","author":"Yilmaz","year":"2020","journal-title":"J Oncol Pharm Pract."},{"key":"10.1016\/j.intimp.2024.111606_b0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2020.04.008","article-title":"Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab","volume":"133","author":"Tsukita","year":"2020","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.intimp.2024.111606_b0160","article-title":"Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma","volume":"32","author":"Hata","year":"2020","journal-title":"Urol Case Rep."},{"key":"10.1016\/j.intimp.2024.111606_b0165","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2020.05.015","article-title":"Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient","volume":"146","author":"Ito","year":"2020","journal-title":"Lung Cancer."},{"issue":"6","key":"10.1016\/j.intimp.2024.111606_b0170","doi-asserted-by":"crossref","first-page":"e235249","DOI":"10.1136\/bcr-2020-235249","article-title":"Rare case of life-threatening thrombocytopenia occurring after radiotherapy in a patient treated with immune checkpoint inhibitor","volume":"13","author":"Hendrix","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"2","key":"10.1016\/j.intimp.2024.111606_b0175","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4081\/cp.2020.1249","article-title":"Severe immune thrombocytopenia induced by a single dose of nivolumab in a patient with advanced non-small cell lung cancer","volume":"10","author":"Khorasanchi","year":"2020","journal-title":"Clin Pract."},{"issue":"1","key":"10.1016\/j.intimp.2024.111606_b0180","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1111\/jdv.16829","article-title":"Severe thrombocytopenia and excellent response following combined immune checkpoint inhibition for metastatic malignant melanoma","volume":"35","author":"Wang","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.intimp.2024.111606_b0185","first-page":"101170","article-title":"Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma","volume":"31","author":"Sakakibara-Konishi","year":"2020","journal-title":"Respir Med Case Rep."},{"key":"10.1016\/j.intimp.2024.111606_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.530478","article-title":"Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2024.111606_b0195","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1177\/1078155220981155","article-title":"Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review","volume":"27","author":"Fu","year":"2021","journal-title":"J Oncol Pharm Pract."},{"issue":"3","key":"10.1016\/j.intimp.2024.111606_b0200","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12328-021-01352-3","article-title":"A case of gastric cancer that developed thrombocytopenia during treatment with nivolumab","volume":"14","author":"Kagaya","year":"2021","journal-title":"Clin J Gastroenterol."},{"issue":"3","key":"10.1016\/j.intimp.2024.111606_b0205","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/bjh.17387","article-title":"Immune thrombocytopenia after immune checkpoint inhibitor therapy","volume":"193","author":"Amanam","year":"2021","journal-title":"Br J Haematol."},{"issue":"5","key":"10.1016\/j.intimp.2024.111606_b0210","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.21037\/apm-21-794","article-title":"Delayed thrombocytopenia as a rare but serious adverse event secondary to immune checkpoint inhibitor: a case report","volume":"10","author":"Zhou","year":"2021","journal-title":"Ann Palliat Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.111606_b0215","doi-asserted-by":"crossref","first-page":"e00799","DOI":"10.1002\/rcr2.799","article-title":"No need to hesitate: immune-related neutropenia and thrombocytopenia that improved by corticosteroids","volume":"9","author":"Kanai","year":"2021","journal-title":"Respirol Case Rep."},{"issue":"6","key":"10.1016\/j.intimp.2024.111606_b0220","doi-asserted-by":"crossref","first-page":"e04227","DOI":"10.1002\/ccr3.4227","article-title":"Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use","volume":"9","author":"Dougherty","year":"2021","journal-title":"Clin Case Rep."},{"issue":"20","key":"10.1016\/j.intimp.2024.111606_b0225","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1111\/1759-7714.14106","article-title":"Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report","volume":"12","author":"Makiguchi","year":"2021","journal-title":"Thorac Cancer."},{"issue":"5","key":"10.1016\/j.intimp.2024.111606_b0230","first-page":"280","article-title":"Severe autoimmune-mediated thrombocytopenia in an elderly woman","volume":"34","author":"Wei","year":"2021","journal-title":"Natl Med J India. Sep-Oct"},{"key":"10.1016\/j.intimp.2024.111606_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790051","article-title":"Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review","volume":"12","author":"Xie","year":"2021","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2024.111606_b0240","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2169\/internalmedicine.7581-21","article-title":"Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy","volume":"61","author":"Tamanoi","year":"2022","journal-title":"Intern Med."},{"key":"10.1016\/j.intimp.2024.111606_b0245","doi-asserted-by":"crossref","first-page":"395.e1","DOI":"10.1016\/j.ajem.2022.03.030","article-title":"Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor","volume":"56","author":"Chong","year":"2022","journal-title":"The American Journal of Emergency Medicine"},{"issue":"7","key":"10.1016\/j.intimp.2024.111606_b0250","article-title":"Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report","volume":"3","author":"Tanaka","year":"2022","journal-title":"JTO Clin Res Rep."},{"issue":"5","key":"10.1016\/j.intimp.2024.111606_b0255","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol Immunother."},{"key":"10.1016\/j.intimp.2024.111606_b0260","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer."},{"issue":"20","key":"10.1016\/j.intimp.2024.111606_b0265","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.3390\/cancers14205030","article-title":"Immune checkpoint inhibitor-related cytopenias: about 68 cases from the French Pharmacovigilance Database","volume":"14","author":"Martin","year":"2022","journal-title":"Cancers (basel)."},{"issue":"44","key":"10.1016\/j.intimp.2024.111606_b0270","doi-asserted-by":"crossref","first-page":"27460","DOI":"10.18632\/oncotarget.25446","article-title":"PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy","volume":"9","author":"Rolfes","year":"2018","journal-title":"Oncotarget."},{"issue":"6","key":"10.1016\/j.intimp.2024.111606_b0275","first-page":"612","article-title":"Thrombocytopenia","volume":"85","author":"Gauer","year":"2012","journal-title":"Am Fam Physician."},{"issue":"23","key":"10.1016\/j.intimp.2024.111606_b0280","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"issue":"36","key":"10.1016\/j.intimp.2024.111606_b0285","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2024.111606_b0290","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00262-020-02536-5","article-title":"Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort","volume":"69","author":"Naqash","year":"2020","journal-title":"Cancer Immunol Immunother."},{"issue":"5","key":"10.1016\/j.intimp.2024.111606_b0295","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jgo.2021.02.002","article-title":"Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer","volume":"12","author":"Johns","year":"2021","journal-title":"J Geriatr Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924001243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924001243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:40:21Z","timestamp":1769229621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924001243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":59,"alternative-id":["S1567576924001243"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111606","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111606"}}